DYN Q4 2023 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$68M

Net Income

-$67M

EPS (Diluted)

$-1.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$35M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$165M

Total Liabilities

$74M

Stockholders' Equity

$91M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$68M	-$40M	-68.6%
Net Income	-$67M	-$39M	-71.6%